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analyze the differences in the expression levels of TIMM9 in both tumor and nontumor tissues
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j.jfma.2016.08.007TIMM9 expression and clinicopathologic parameters were significant. Time-to-event endpoints
for clinicopathologic parameters were plotted using the KaplaneMeier method, and statistical
significance was determined using univariate log-rank tests. Cox proportional hazard model
was used for multivariate analysis to determine the independence of prognostic effects of
TIMM9 expression.
Results: A borderline association was found between overexpression of TIMM9 and vascular in-
vasion (p Z 0.0887). Patients with high expression levels of TIMM9 achieved a significantly
lower disease-free survival rate compared with those with low expression levels
(p Z 0.005). Multivariate Cox regression analysis showed that overexpression of TIMM9 was
an independent prognostic marker for GC (p Z 0.011).
Conclusion: Overexpression of TIMM9 can be used as a marker to predict the outcome of pa-
tients with GC.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
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Gastric cancer (GC) ranks as the second most frequent
cause of cancer-related mortality.1 In Taiwan, GC results in
more than 2000 deaths annually (http://www.mohw.gov.
tw/CHT/DOS/Statistic.aspx?f_list_noZ312&fod_list_noZ6
201). The outcome of this common malignancy remains
unsatisfactory because of poor understanding of the path-
ogenesis of GC and the lack of specific target gene ther-
apy.2,3 In recent decades, several studies have suggested
that genetic alterations may play a role in the development
and progression of GC.4 Studies in molecular pathology,
both ours and others, may help clarify the pathogenesis of
GC and may reveal useful prognostic molecular
markers.5e10
An elaborate mitochondrial translocation system is
necessary to transport protein precursors to their correct
intramitochondrial destinations.11,12 Cancer cells amplify
their capacity for mitochondrial oxidative metabolism and
“steal” high-energy mitochondrial fuels from adjacent
stromal cells.13,14 In direct support of this hypothesis, ge-
netic induction of mitochondrial dysfunction in cancer-
associated fibroblasts dramatically promotes both local
tumor growth and distant cancer cell metastasis.15,16
Translocases of inner mitochondrial membrane (TIMM)
family consists of a group of evolutionarily conserved pro-
teins that participate in the import and insertion of multi-
pass transmembrane proteins into the mitochondrial inner
membrane.17 Proteomic analysis showed an increase of
TIMM17A protein levels in breast cancer cells, and the in-
crease was validated by immunoblotting and immunohis-
tochemistry. Ductal carcinoma in situ and invasive ductal
carcinoma of the breast displayed strong staining, whereas
the adjacent normal epithelia and stromal cells displayed
negative staining.18 Similarly, Sotgia et al19 demonstrated
that 15 markers of mitochondrial biogenesis, including
TIMM9 and TIMM17A, selectively labeled epithelial breast
cancer cells and were largely absent from adjacent tumor
stromal cells.
The clinical importance of TIMM family has gained
increasing attention in recent years, with reports suggest-
ing that TIMM may contribute to the clinical outcome.Lin C-C, et al., High expression
tric cancer, Journal of the FoStudies by both Xu et al18 and Salhab et al20 have reported
that TIMM17A expression was significantly associated with
unfavorable pathological parameters, including tumor
grade, nodal positivity, and stage, as well as with adverse
clinical outcomes such as overall and disease-free survival.
Thus, TIMM17A is a promising diagnostic and prognostic
marker for breast cancer patients.
To date, the prognostic significance of TIMM9 expression
level in human GC has not been established. This study
investigated the correlations between TIMM9 expression and
clinicopathologic parameters, and evaluated the significance
of TIMM9 in predicting the prognosis for patients with GC.Materials and methods
Ethics statements
The Institutional Review Board at Wan Fang Hospital, Tai-
pei, Taiwan, approved the tissue acquisition protocol for
the immunohistochemical, immunoblotting, and quantita-
tive real-time polymerase chain reaction (PCR) study
(Approval Number: 99049). Written informed consent was
obtained from each participant before tissue acquisition.Participants and specimens
The patient cohort comprised 140 consecutive GC cases
from 1998 through 2011 documenting pathologic and clin-
ical factors and clinical outcome. All the cases in this study
received radical total or subtotal gastrectomy with D2 or D3
lymph node dissection. None of our study patients had
received preoperative chemotherapy and/or radiotherapy.
The nontumor portion was obtained from grossly normal
gastric mucosa, separate from the tumor, in resected
gastric specimen. Clinicopathologic parameters of GCs
were determined according to the American Joint Com-
mittee on Cancer (AJCC) classification. The follow-up
duration for disease-free survival was defined as the
period between the operation date and the day of relapse,
according to the patient’s chart. For each patient, weof mitochondrial intermembrane chaperone TIMM9 represents a
rmosan Medical Association (2016), http://dx.doi.org/10.1016/
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determine the TIMM9 expression.
Immunohistochemical analysis
TIMM9 expression was analyzed with immunohistochemistry.
Paraffin-embedded tissue blocks were sectioned at 5 mmand
transferred to microscope slides (Muto Pure Chemicals Co.
Ltd., Tokyo, Japan). The small intestinewasusedas a positive
control for TIMM9. The negative control entailed omission of
the primary antibody and incubation with phosphate buffer
saline. Sections were dewaxed with xylene and then rehy-
drated in graded alcohols. Deparaffinized sections were
incubated in pH 6.0 citrate buffer for 40 minutes at 95C on a
hotplate to retrieve antigens. Further antigen blocking was
performed using Dako REAL Peroxidase-Blocking Solution
(Dako North America, Carpinteria, CA, USA) for 5 minutes.
The slides were subsequently incubated with primary anti-
body: mouse monoclonal anti-TIMM9 antibody (Abnova, Tai-
pei, Taiwan, Catalogue Number H00026520-M01, Lot Number
E3041-1D6, TIMM9 full-length recombinant protein with
glutathione S-transferase tag was used as the antigen) for
1 hour at room temperature, at a dilution of 1:150. Detection
of the immunoreactive staining was conducted using the
avidinebiotineperoxidase complex method according to the
manufacturer’s instructions (Dako REAL EnVision Detection
System, Dako North AMerica). After incubation with dia-
minobenzidine for 5 minutes, the sections were counter-
stained with hematoxylin and mounted in Dako Faramount
Aqueous Mounting Medium (Dako North America) for micro-
scopic interpretation. Semiquantitative scoring of intensity
(0, no staining; 1, weak staining; 2, strong staining) and
fraction of positive cancer cells (0, no staining; 1, less than
half; 2, more than half) was undertaken. The final score was
calculated for each sample by multiplying the intensity and
the percentage of immunostaining: 0, no staining; 1, weak
staining; 2, moderate staining; 4, strong staining. Sections
with a score of 0 or 1 displayed low expression of TIMM9,
whereas those that scored 2 or 4 were defined as having high
expression or overexpression of TIMM9. Clinical data collec-
tion and immunohistochemical analysis were performed
independently of each other, in an investigator-blinded
study.
RNA extraction and complementary DNA synthesis
According to the manufacturer’s instructions, total RNA
from 10 tumor and nontumor pairs of gastric tissues was
isolated using an RNA extraction kit (Sigma, St. Louis, MO,
USA). RNA quality was analyzed using an Agilent 2100 Bio-
analyzer (Agilent, Santa Calra, CA, USA). The values of RNA
integrity number of all 20 samples were higher than 7.
Complementary DNA synthesis was performed as described
in our previous study.21 Synthesized complementary DNA
was stored at 20C until use.
Primers and quantitative real-time PCR
Primers of TIMM9 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), an internal control, and real-time PCR
master mix were purchased from Sigma. The expressionPlease cite this article in press as: Lin C-C, et al., High expression
negative prognostic marker in gastric cancer, Journal of the For
j.jfma.2016.08.007levels of the target genes were measured using quantitative
real-time PCR in the Illumina Eco System (Illumina, San
Diego, CA, USA). Threshold cycle (Ct) is the fractional cycle
number at which the fluorescence generated by cleavage of
the probe exceeds a fixed level above baseline. For a
chosen threshold, a smaller starting copy number results in
a higher Ct value. The amount of TIMM9 messenger RNA
(mRNA) in tumor or nontumor tissues, standardized against
the amount of GAPDH mRNA, was expressed as DCtumor or
DCnontumor Z Ct (TIMM9) e Ct (GAPDH).Cell culture
Human normal (Hs738.St/Int) gastric cell line was obtained
from the American Type Culture Collection (Manassas, VA,
USA; Catalogue Number CRL-7869). Gastric cancer (AGS,
NCI-N87, TMC-1, and TSGH 9201) cell lines were obtained
from the Bioresource Collection and Research Center
(BCRC; Hsinchu, Taiwan; Catalogue Numbers BCRC 60102,
60217, 60379, and 60146, respectively). Cell lines were
authenticated by the American Type Culture Collection and
BCRC cell biology program and were not passaged for longer
than 6 months before original frozen stocks were thawed
and used or purchasing a new cell aliquot. Cells were
cultured in Dulbecco’s Modified Eagle Medium (Hs738.St/
Int), F-12K (AGS), and RPMI-1640 (NCI-N87, TMC-1, and
TSGH 9201) media supplemented with 10% fetal bovine
serum, 100 units/mL penicillin G, 100 mg/mL streptomycin
sulfate, and 250 ng/mL amphotericin B.Total protein preparation
Total proteins were extracted using M-PER Mammalian Pro-
tein Extraction Reagent and T-PER Tissue Protein Extraction
Reagent (Pierce Biotechnology, Rockford, IL, USA), accord-
ing to the manufacturer’s instructions. The samples were
stored at 80C until used. The protein concentration was
determined using a BCA Protein Assay Kit (Pierce Biotech-
nology) with bovine serum albumin as a standard.Immunoblotting
Denatured protein samples were subjected to 18% sodium
dodecyl sulfate polyacrylamide gel electrophoresis. Pro-
teins were transferred to nitrocellulose membranes, and
blocked blots were incubated at 4C overnight with anti-
TIMM9 polyclonal antibody (1:100 dilution). GAPDH was
used as an internal control for equal protein loading (mouse
monoclonal anti-GAPDH antibody was purchased from Mil-
lipore, Billerica, MA, USA; Catalogue Number MAB374, Lot
Number JC1682928, GAPDH from rabbit muscle was used as
the antigen). Blots were further incubated with secondary
antibodies conjugated with peroxidase (Sigma) for 1 hour at
room temperature. They were then incubated with Western
Lighting ECL Pro Chemiluminescence Substrate (Perki-
nElmer, Waltham, MA, USA), and exposed to a Fuji medical
x-ray film (Fuji Photo Film Co., Tokyo, Japan). Image pro-
cessing was performed using Fuji Image Gauge software.of mitochondrial intermembrane chaperone TIMM9 represents a
mosan Medical Association (2016), http://dx.doi.org/10.1016/
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For short hairpin RNA treatment, AGScells were infectedwith
lentiviral vectors (one TIMM9-short hairpin RNA construct,
clone identification: TRCN0000151300 and one control, clone
identification: pLKO_TRC025, purchased from the National
RNAi Core Facility, Taipei, Taiwan) and stable clones resistant
to puromycin (Santa Cruz, Dallas, TX, USA) were selected.In-vitro invasion assay
The cell invasion capability was examined using a Cell In-
vasion Assay Kit (Merck Millipore, Darmstadt, Germany),
following the manufacturer’s instructions. Complete media
were first added to 24-well plates. The cells (2  105) in
serum-free media were added to ECMatrix-layered cell
culture inserts (containing 8-mm pore size polycarbonate
membranes) and cultured for 24 hours. Before staining, the
cells on the upper surface were removed. Inserts were then
dipped in the staining solution to stain invaded cells on the
lower surface of the membranes. The cultures were pho-
tographed (100 magnification, with Leica DMIRB micro-
scope, Leica, Wetzlar, Germany).Statistical analysis
Paired t tests were used to assess the difference in TIMM9
expression between tumor and nontumor tissues for each
patient. We examined several clinicopathologic parameters:
age, sex, depth of invasion, nodal status, distant metastasis,
stage, degree of differentiation, and vascular permeation.
The correlation between TIMM9 expression and each clini-
copathologic parameter was examined using c2 test. The
time-to-event endpoints for all clinicopathologic parame-
ters were plotted using the KaplaneMeier method, and the
degree of significance was calculated using the univariate
log-rank test. p < 0.05 was considered significant. Parame-
ters that emerged as significant (p < 0.05) in the univariate
analysis were entered as variables in the multivariate Cox
regression model, and hazard ratio (HR) and independence
of prognostic impact were determined in a stepwise back-
ward fashion. All data were analyzed using SPSS software
version 17.0 (SPSS, Chicago, IL, USA).Figure 1 Expression of translocase of inner mitochondrial mem
immunohistochemistry. (A) A sample with low expression level o
Magnification: 200.
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Basic data
This study enrolled 140 patients with GC; 91 of the 140
patients were men and 49 of the 140 patients were women
(Supplementary Table 1). The patients’ ages ranged from
34 years to 96 years at first diagnosis (mean, 69.2 years).
Based on the AJCC classification, 29 patients were at Stage
I, 34 were at Stage II, 62 were at Stage III, and 15 were at
Stage IV. The follow-up period for all patients ranged from
0 months to 141.3 months (mean, 29.5 months). Eighty-
eight patients died during follow-up.
TIMM9 expression was upregulated and associated
with vascular invasion in GC
We used immunohistochemical analysis to investigate the
expression of TIMM9 in tissues obtained from our study
patients (Figures 1A and 1B). TIMM9 expression was signif-
icantly higher in tumor tissues than in nontumor tissues
(p < 0.001). Overexpression of TIMM9 (scores of 2 or 4) was
observed in 54 of the 140 patients (38.6%). In addition,
quantitative real-time PCR analysis demonstrated that the
expression of TIMM9 mRNA was substantially increased in
tumor tissues compared with nontumor tissues (Table 1,
Figure 2A). Immunoblotting analysis also demonstrated that
the expression of TIMM9 was substantially increased in
GC cells and tissues compared with normal cells and tissues
(Figure 2B). As shown in Table 2, overexpression of TIMM9
was associated with vascular invasion with a borderline
significance (pZ 0.0887). TIMM9 was knocked down in AGS
cells to further support the data from immunohistochem-
ical analysis. As shown in Figure 3, inhibiting TIMM9
decreased AGS cell invasion. No significant association was
found between the overexpression of TIMM9 and other
clinicopathologic parameters.
Overexpression of TIMM9 as a prognostic marker for
GC
Correlations of clinical outcomes with TIMM9 expression are
shown in Figure 4. Overexpression of TIMM9 was signifi-
cantly associated with inferior disease-free survivalbrane 9 (TIMM9) in gastric cancer specimens analyzed using
f TIMM9; (B) a sample with high expression level of TIMM9.
of mitochondrial intermembrane chaperone TIMM9 represents a
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Table 1 Quantification of translocase of inner mitochon-
drial membrane 9 (TIMM9) messenger RNA expression using
quantitative real-time polymerase chain reaction in 10
tumor and nontumor pairs of gastric tissues.
No. Nontumor Tumor
TIMM9 b-
Actin
DCnontumor TIMM9 b-
Actin
DCtumor
WH9802600 30.30 20.68 9.62 27.22 20.34 6.88
WH0005527 30.53 21.35 9.18 28.00 20.98 7.02
WH0102450 30.78 21.81 8.97 27.25 21.51 5.74
WH0203703 29.28 20.16 9.12 24.83 20.44 4.39
WH0304023 30.03 19.97 10.06 25.97 19.62 6.35
WH0502185 29.91 20.46 9.45 25.29 20.12 5.17
WH0609650 30.20 20.83 9.37 26.28 20.65 5.63
WH0808921 30.32 20.55 9.77 27.22 20.08 7.14
WH0908780 29.38 20.71 8.67 27.40 20.49 6.91
WH1103763 31.22 21.09 10.13 27.41 20.85 6.56
Figure 2 Expression of translocase of inner mitochondrial
membrane 9 (TIMM9) in gastric tissues and cell lines. (A) TIMM9
messenger RNA expression in gastric tissues shown in Table 1
was plotted; (B) TIMM9 protein expression was examined in
five gastric cells and two tumor and nontumor pairs of gastric
tissues. GAPDH Z glyceraldehyde-3-phosphate dehydrogenase.
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j.jfma.2016.08.007(Figure 4A; pZ 0.005). Five-year disease-free survival rate
in patients with high expression levels of TIMM9 was of
27.6%, whereas that in patients with low expression levels
was 56.6%. Because the tumor stage is a critical prognostic
marker of GC, low-stage (Stage I and II) and high-stage GC
(Stage III and IV) were used independently to determine the
effect of TIMM9 overexpression on the prognosis. We found
that in high-stage GC, shorter disease-free survival was
significantly associated with overexpression of TIMM9
(Figure 4B; p Z 0.040). However, in low-stage GC, the as-
sociation between overexpression of TIMM9 and disease-
free survival was only borderline significant (Figure 4C;
p Z 0.066).
The results of univariate analysis of the prognostic
markers of GC are presented in Table 3. Disease-free sur-
vival was significantly correlated with each of the
following: overexpression of TIMM9 (p Z 0.007), depth of
invasion (p < 0.001), nodal status (p < 0.001), distant
metastasis (p < 0.001), stage (p < 0.001), degree of dif-
ferentiation (pZ 0.014), and vascular invasion (p < 0.001).Table 2 Translocase of inner mitochondrial membrane 9
(TIMM9) expression in gastric cancer and its correlation with
clinicopathologic parameters.
Variable n TIMM9 expression p*
Score Z 0
or 1
(n Z 86)
Score Z 2
or 4
(n Z 54)
Age (y) 0.1853
66 89 51 38
<66 51 35 16
Sex 0.4892
Male 91 54 37
Female 49 32 17
Lauren classification 0.8944
Intestinal 95 58 37
Diffuse 45 28 17
Depth of invasion 0.1977
T1 þ T2 37 26 11
T3 þ T4 103 60 43
Nodal status 0.1053
N0 45 32 13
N1 þ N2 þ N3 95 54 41
Distant metastasis 0.4955
Absent 125 78 47
Present 15 8 7
Stage 0.4221
I þ II 63 41 22
III þ IV 77 45 32
Degree of
differentiation
0.8532
Poor 61 38 23
Well to moderate 79 48 31
Vascular invasion 0.0887
Absent 40 29 11
Present 100 57 43
* All statistical tests were two-tailed and the significance level
was p < 0.05.
of mitochondrial intermembrane chaperone TIMM9 represents a
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Figure 3 Effect of translocase of inner mitochondrial mem-
brane 9 (TIMM9) knockdown in AGS cells on cell invasion. (A)
AGS/scrambled control; (B) AGS/TIMM9 short hairpin RNA.
Magnification: 100.
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survival was significant even after controlling for other
well-known prognostic markers in multivariate analysis
(Table 4). In multivariate analysis, overexpression of TIMM9
(HR Z 0.531, 95% confidence interval Z 0.325e0.867,
p Z 0.011) and distant metastasis (HR Z 0.133, 95% con-
fidence interval Z 0.052e0.336, p < 0.001) were prog-
nostically independent.Figure 4 Survival analysis of gastric cancer (GC) patients
stratified by translocase of inner mitochondrial membrane 9
(TIMM9) immunoreactivity (low TIMM9: score Z 0 or 1; high
TIMM9: score Z 2 or 4). (A) Disease-free survival in 140 GC
patients; (B) shows the disease-free survival in 77 high-stage
GC (Stages III and IV) patients; (C) shows the disease-free
survival in 63 low-stage GC (Stages I and II) patients. All sta-
tistical tests were two-sided. Significance level: p < 0.05.
Cum Z cumulative.Discussion
Surgical resection is generally considered the best treat-
ment to improve the prognosis when early diagnosis of GC is
successful.22 Unfortunately, most cases of GC are diagnosed
at a locally advanced stage. To develop novel strategies to
prevent and treat GC, a comprehensive understanding of the
molecular mechanisms underlying the development of this
deadly neoplasm is essential. In particular, identification of
the molecules altered during cancer progression can provide
valuable tools as prognostic markers or therapeutic targets.
Mitochondria have an established role in cell prolifera-
tion. In keeping with this, an emerging role of mitochondria
in carcinogenesis is supported by an increasing body of evi-
dence.23 Mitochondrial function is profoundly dependent on
the import of cytosolic proteins, and defects in the trans-
location system can result in significant functionalPlease cite this article in press as: Lin C-C, et al., High expression of mitochondrial intermembrane chaperone TIMM9 represents a
negative prognostic marker in gastric cancer, Journal of the Formosan Medical Association (2016), http://dx.doi.org/10.1016/
j.jfma.2016.08.007
Table 3 Univariate analysis of prognostic markers in 140
patients with gastric cancer.
Variable HR (95% CI) p*
TIMM9 0.516 (0.319e0.835) 0.007
Low expression
High expression
Age (y) 1.006 (0.987e1.025) 0.560
66
<66
Sex 0.684 (0.405e1.155) 0.155
Male
Female
Lauren classification 0.687 (0.417e1.134) 0.142
Intestinal
Diffuse
Depth of invasion 0.189 (0.082e0.439) <0.001
T1 þ T2
T3 þ T4
Nodal status 0.208 (0.103e0.422) <0.001
N0
N1 þ N2 þ N3
Distant metastasis 0.080 (0.033e0.196) <0.001
Absent
Present
Stage 0.192 (0.106e0.349) <0.001
I þ II
III þ IV
Degree of differentiation 1.824 (1.127e2.953) 0.014
Poor
Well to moderate
Vascular invasion 1.185 (0.084e0.408) <0.001
Absent
Present
* All statistical tests were two-tailed and the significance level
was p < 0.05.
CI Z confidence interval; HR Z hazard ratio;
TIMM9 Z translocase of inner mitochondrial membrane 9.
Table 4 Multivariate analysis of prognostic markers in 140
patients with gastric cancer.
Variable HR (95% CI) p*
TIMM9 0.531 (0.325e0.867) 0.011
Low expression
High expression
Depth of invasion 0.547 (0.204e1.468) 0.231
T1 þ T2
T3 þ T4
Nodal status 0.739 (0.269e2.032) 0.558
N0
N1 þ N2 þ N3
Distant metastasis 0.133 (0.052e0.336) <0.001
Absent
Present
Stage 0.427 (0.171e1.069) 0.069
I þ II
III þ IV
Degree of differentiation 1.912 (0.892e4.099) 0.095
Poor
Well to moderate
Vascular invasion 0.551 (0.220e1.378) 0.203
Absent
Present
* All statistical tests were two-tailed and the significance level
was p < 0.05.
CI Z confidence interval; HR Z hazard ratio;
TIMM9 Z translocase of inner mitochondrial membrane 9.
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promote the development of several human malignancies.24
The expression of mitochondrial protein TIMM9 in human
cancers varies according to cancer type. The survey of a
public human protein atlas database indicated that TIMM9
protein level is elevated in numerous human cancers,
including thyroid, lung, and liver cancer, whereas it is
decreased in pancreatic cancer. Our literature review iden-
tified only one study, by Wang et al,25 that investigated the
expression of TIMM9 in human GC. This study revealed that
TIMM9 protein expression level was not increased in patients
with GC. The failure to reach a significant difference be-
tween tumor and nontumor gastric tissues may be due to the
small sample size (only 12 tumor/nontumor paired tissues
were analyzed). In the present study, we assessed the
expression levels of TIMM9 in gastric tissues obtained from
140 GC patients. The results of our study were inconsistent
with those of Wang et al25 and suggested that TIMM9
expression was elevated in gastric tumor tissues compared
with nontumor gastric tissues. The immunoblotting results
confirmed that TIMM9expressionwas higher inGC tissues and
cells than in normal gastric tissues and cells.Please cite this article in press as: Lin C-C, et al., High expression
negative prognostic marker in gastric cancer, Journal of the For
j.jfma.2016.08.007Statistical analysis suggested that overexpression of
TIMM9 in GC tissues was closely correlated with vascular in-
vasion. Data from in vitro cell invasion assay further support
this correlation. However, the reason for this relationship
betweenTIMM9overexpression and vascular invasion remains
unclear. The only one line of evidence comes from the studies
conducted by Ishikawa et al26 and Du et al.27 Ishikawa and her
colleagues26 treated the high-metastatic mouse tumor cells
with reactive oxygen species (ROS) scavengers and examined
their effects on the amounts of ROS and their metastatic
ability. The results indicated that the intracellular amount of
ROS will affect their metastatic potential in mouse model.26
However, Du et al27 showed that arsenic treatment results in
increased intracellular levels of ROS and TIMM18 in yeast.
Their results also suggested that TIMM18 probably acted
downstream of ROS formation. Direct evidence for the rela-
tionship betweenTIMM18 andmetastasis are still insufficient.
Furthermore, whether the reason for TIMM9 is the same as
that of TIMM18 also warrants investigation.
Precise prediction of the risk of recurrence of GC would
assist in minimizing the adverse effects and maximizing the
therapeutic effect of the treatment. Of the available
prognostic markers for GC, the AJCC stage is most impor-
tant. However, the prognosis varies even among patients at
the same disease stage; hence, alternative prognostic
markers for GC are required. Mitochondrial markers have
been intensively pursued in recent years. Wang et al25
demonstrated that in GC patients, a strong association
existed between increased inhibin beta A (INHBA) expres-
sion and poor patient survival. Similarly, Wang et al25
showed that overexpression of CISD2 protein was anof mitochondrial intermembrane chaperone TIMM9 represents a
mosan Medical Association (2016), http://dx.doi.org/10.1016/
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studies by both Xu et al18 and Salhab et al20 indicated that a
strong association existed between increased TIMM17A
expression and poor patient survival in cases of GC. The
role of TIMM9 in tumor prognosis is still unknown. The re-
sults of this study indicated that TIMM9 overexpression was
inversely correlated with patient survival. Our study was
the first to report that overexpression of TIMM9 can predict
poorer outcomes for patients with GC. Overexpression of
TIMM9 appears to be a useful marker to predict outcomes in
patients with GC who have received surgical resection of
the tumor. Thus, patients with GC who display over-
expression of TIMM9 should be followed-up carefully.
The limitations of this study include the small sample
size for the GC cohort. Accordingly, additional cohort
studies would be helpful to confirm our findings.
In summary, this study provides evidence for the clinical
significance of overexpressed TIMM9 in patients with GC.
Our findings indicate that targeting TIMM9 might provide a
new therapeutic modality for the treatment of GC.
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